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Abstract
Importance
Febrile neutropenia (FN) is the most common oncologic emergency and is among the most
deadly. Guidelines recommend risk stratification and outpatient management of both pediat-
ric and adult FN patients deemed to be at low risk of complications or mortality, but our prior
single-center research demonstrated that the vast majority (95%) are hospitalized.
Objective
From a nationwide perspective, to determine the proportion of cancer patients of all ages
hospitalized after an emergency department (ED) visit for FN, and to analyze variability in
hospitalization rates. Our a priori hypothesis was that >90% of US cancer-associated ED
FN visits would end in hospitalization.
Design
Analysis of data from the Nationwide Emergency Department Sample, 2006–2014.
Setting
Stratified probability sample of all US ED visits.
Participants
Inclusion criteria were: (1) Clinical Classification Software code indicating cancer, (2) diag-
nostic code indicating fever, and (3) diagnostic code indicating neutropenia. We excluded
visits ending in transfer.
Exposure
The hospital at which the visit took place.
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Main outcomes and measures
Our main outcome is the proportion of ED FN visits ending in hospitalization, with an a priori
hypothesis of >90%. Our secondary outcomes are: (a) hospitalization rates among subsets,
and (b) proportion of variability in the hospitalization rate attributable to which hospital the
patient visited, as measured by the intra-class correlation coefficient (ICC).
Results
Of 348,868 visits selected to be representative of all US ED visits, 94% ended in hospitaliza-
tion (95% Confidence Interval [CI] 93–94%). Each additional decade of age conferred 1.23x
increased odds of hospitalization. Those with private (92%), self-pay (92%), and other
(93%) insurance were less likely to be hospitalized than those with public insurance (95%,
odds ratios [OR] 0.74–0.76). Hospitalization was least likely at non-metropolitan hospitals
(84%, OR 0.15 relative to metropolitan teaching hospitals), and was also less likely at metro-
politan non-teaching hospitals (94%, OR 0.64 relative to metropolitan teaching hospitals).
The ICC adjusted for hospital random effects and patient and hospital characteristics was
26% (95%CI 23–29%), indicating that 26% of the variability in hospitalization rate was attrib-
utable to which hospital the patient visited.
Conclusions and relevance
Nearly all cancer-associated ED FN visits in the US end in hospitalization. Inter-hospital var-
iation in hospitalization practices explains 26% of the limited variability in hospitalization
decisions. Simple, objective tools are needed to improve risk stratification for ED FN
patients.
Introduction
The National Cancer Institute has made research on oncologic emergencies a priority.[1,2]
Large-scale, multi-state research on emergency department (ED) use by adults and children
with cancer was limited until the recent publication of findings from the Nationwide Emer-
gency Department Sample (NEDS).[3,4] Though cancer chemotherapy-associated febrile neu-
tropenia (FN) is the most common oncologic emergency, one of these publications (the one
focused on adults) did not address FN.[4] This likely resulted from the lack of a unique code
for FN in the International Classification of Diseases (ICD9).
FN can be deadly, but many patients are stable and guidelines recommend discharge with
oral antibiotics in adults deemed to be at low risk by a Multinational Association for Support-
ive Care in Cancer (MASCC) score>20, and absence of other indicators of risk.[5,6] At our
cancer-center-associated ED, 25% of adults with FN were classified as low risk by MASCC,[7]
and in the original MASCC study, 63% were.[8] Furthermore, pediatric-specific guidelines
also recommend risk stratification and outpatient management of a low-risk cohort.[9]
Despite this, we found that only 5% of all adult FN patients are discharged to home from our
ED.[7,10] This discordance of guidelines and practice is likely multifactorial, in part due to
lack of guideline awareness, the complexity of the guidelines, and because the MASCC score
has a negative predictive value for complications of only 83% and therefore is not trusted.
[11,12] However, we suspected that differences in regional practice patterns, hospital teaching
FN hospitalization in US EDs
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status, case mix or cancer staging could possibly impact hospitalization rates for low-risk can-
cer patients with FN.
We analyzed NEDS data in order to describe hospitalization practices for ED patients with
cancer-associated FN on a nationwide scale. Based on our previous work, we hypothesized
that>90% of these patients would be hospitalized and that hospitalization rates would vary
between institutions.[5–7]
Methods
NEDS is a stratified probability sample of approximately 20% of all hospital-based US EDs.
[13] It includes ICD-9 codes, patient demographics, and hospital characteristics. Observations
are made at the visit level, and are weighted according to the sampling scheme, which allows
for national estimates. All data are anonymous and publicly available, and the study was con-
sidered exempt by our IRB.
For 2006–2014, we selected patients with Healthcare Cost and Utilization Project (HCUP)
Clinical Classification Software (CCS) codes 11–45, indicating cancer. We then searched all
diagnostic fields for codes indicating both fever (7806, 78060 and 7806), and neutropenia
(2880, 28809, 28800, 28803, 28850, 2885 and 28859), in order to derive our sample of interest.
We excluded visits ending in death or transfer to another facility. Visits with missing data were
also excluded from the model.
Our main outcome is the proportion of FN ED visits ending in hospitalization. Our second-
ary outcomes are hospitalization rates by age, sex, median household income, payer, and hos-
pital teaching status; and inter-hospital variation in FN hospitalization rates, calculated via the
intra-class correlation coefficient (ICC). The ICC quantifies the proportion of total variation
that is attributable to inter-hospital differences in hospitalization rate.
We fit a logistic regression model with hospitalization rate as the outcome, hospital as the
exposure and the following covariates: age, sex, median household income, payer, hospital sta-
tus, year of visit, and number of FN visits per hospital. Variables were selected a priori. We
used backward elimination to remove predictors with p�0.05 and chose the final model based
on the lowest Akaike Information Criterion. To calculate the ICC, we fit a multilevel mixed
effects model, and calculated the ICC from the covariance parameter estimates.
Results
There were 9,064,754 records with a cancer CCS code, indicating 40,806,565 visits by patients
with cancer nationwide (95%Confidence Interval [CI] 39,165,555–42,447,575). Of all US ED
visits, 3.5% were made by patients with cancer (95%CI 3.4%-3.6%). Among the cancer visits,
79,428 had FN, representing 361,456 US cancer-associated FN visits (95%CI 336,568–
386,343). After exclusion of deaths and transfers, 348,868 visits were available for analysis
(95%CI 324,104–373,632). For our main outcome, 94% of visits ended in hospitalization (95%
CI 93–94%) (Table 1).
Age, payer category, and hospital status were associated with likelihood of hospitalization
(Table 2). Each decade of age conferred 1.23 times the odds of hospitalization. A patient pre-
senting to a metropolitan teaching hospital was nearly seven times as likely to be hospitalized
as a patient presenting to a non-metropolitan hospital (95% versus 84%, respectively). A given
hospital’s number of FN ED visits per year did not predict the odds of hospitalization (odds
ratio [OR] 1.00, 95%CI 1.00–1.00). Adjusting for age, primary payer, visit year, number of FN
ED visits per hospital and hospital status, 26% of the variability in hospitalization rates was
attributable to hospital-to-hospital variability.
FN hospitalization in US EDs
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Discussion
We found that 94% of all US FN ED visits end in hospitalization, confirming our a priori
hypothesis, and consistent with our prior finding of a 95% hospitalization rate at one institu-
tion.[7] Hospitalization rates were slightly lower for pediatric patients, but still>90% for the
entire cohort. Near-universal hospitalization of FN patients is problematic, because hospitali-
zation and prolonged broad-spectrum antibiotic treatment carry risks including C. difficile
colitis, selection of drug-resistant strains, drug toxicity, allergic reactions, drug-drug interac-
tions, acquisition of nosocomial pathogens, exposure to medical errors, catheter-associated
infections, thromboembolism, and financial burdens.[5,6]
Why are nearly all cancer-associated FN ED patients hospitalized? Guidelines recommend
use of the MASCC score and other clinical predictors to determine which adult patients with
cancer should be hospitalized.[5,6] Clinicians are asked to calculate the MASCC score, and for
patients with a score>20, consider discharge if no fewer than 41 additional criteria are fulfilled
Table 1. Characteristics of US ED febrile neutropenia visits, 2006–2014.
Characteristics Proportion of this Subgroup Hospitalized % (95%CI) Number of Patients Percent
Overall 94 (93–94) 348,868 100
Age (years)
� 3 91 (89–93) 13,260 4
4–9 89 (87–91) 19,092 5
10–14 92 (89–94) 9,444 3
15–19 93 (91–95) 8,226 2
20–29 95 (94–96) 11,917 3
30–39 93 (92–94) 16,056 5
40–49 93 (93–94) 32,171 9
50–59 94 (93–94) 59,680 17
60–69 94 (94–95) 82,574 24
70–79 95 (95–96) 68,558 20
80–89 96 (96–97) 26,069 7
� 90 97 (96–99) 1,821 1
Sex
Male 94 (94–95) 172,223 49
Female 94 (93–94) 176,630 51
Median household income quartile
1 (lowest) 93 (93–94) 72,320 21
2 93 (92–94) 85,581 25
3 94 (94–95) 88,855 25
4 (highest) 95 (94–95) 93,820 27
Primary Health Insurance
Public 95 (95–95) 197,511 57
Private 92 (91–93) 133,919 38
Self-pay 92 (91–94) 6,309 2
Other 93 (92–95) 10,649 3
Hospital Status
Metropolitan Teaching 95 (95–96) 207,960 60
Metropolitan, Non-teaching 94 (93–94) 110,530 32
Non-Metropolitan 84 (82–85) 30,378 9
Abbreviations: ED, emergency department; CI, confidence interval
https://doi.org/10.1371/journal.pone.0216835.t001
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(see Table 4 in [6]).[6] This risk stratification method is too cumbersome to be applied in real-
life emergency medicine practice. Moreover, the MASCC score itself is insufficiently accurate,
with a negative predictive value for complications of only 83%.[11] A newer score, the Clinical
Index of Stable Febrile Neutropenia, applies only to solid tumor patients. In summary, current
risk stratification tools are cumbersome and insufficiently accurate which likely explains why
94% of cancer-associated FN ED visits resulted in hospitalization.
We observed variation in hospitalization rates in metropolitan vs. non-metropolitan hospi-
tals and across insurance categories. Of variability in hospitalization rates, 26% was explained
by which hospital the patient visited. Cancer centers tend to be located in metropolitan areas,
and it may be that patients with cancer who experience FN would visit EDs associated with
cancer centers are more likely to be hospitalized than their counterparts visiting non-metro-
politan EDs. This would be perplexing, however, since we would expect EDs affiliated with
cancer centers to be more adept at individualizing care.
Our study has the following limitations. Case ascertainment depended on diagnostic codes,
which may be subject to error. The codes we used to indicate neutropenia did not specify a
neutrophil count of<500/μL2 or 1,000/μL2, both of which are accepted definitions.[5,6,14]
However, we think emergency providers are unlikely to diagnose neutropenia in the absence
of abnormalities of this magnitude, and the high rate of hospitalization we observed suggests
that this was indeed a sample with bona fide immunosuppression.
The lack of a single discharge code describing FN may have also led to an underestimate of
the true number of cases, and our findings of a subset of the combined discharge codes could
be a biased sample towards sicker patients. In some patients, hospitalization is also based on
Table 2. Multilevel mixed effects model for cancer associated febrile neutropenia hospitalization Rates, 2006–
2014.
OR (95%CI) P—value
Age (decades) 1.23 (1.19–1.28) <0.001
Sex
Male Reference
Female 0.96 (0.89–1.03) 0.23
Primary Health Insurance
Public Reference
Private 0.75 (0.69–0.82) <0.001
Self-pay 0.74 (0.56–0.98) 0.03
Other 0.76 (0.58–1.002) 0.052
Visit Year
2006–2008 Reference
2009–2011 0.95 (0.81–1.11) 0.51
2012–2014 1.10 (0.93–1.30) 0.27
Hospital Status
Metropolitan Teaching Reference
Metropolitan, Non-teaching 0.64 (0.54–0.76) <0.001
Non-Metropolitan 0.15 (0.12–0.18) <0.001
ICC % (95%CI): Adjusted for Hospital Random Effects only 34 (31–37)
ICC % (95%CI): Adjusted for Hospital Random Effects & Patient and Hospital
Characteristics
26 (23–29)
Abbreviations: OR, odds ratio; CI, confidence interval; FN, febrile neutropenia; ICC, intra-class correlation
coefficient
https://doi.org/10.1371/journal.pone.0216835.t002
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non-clinical factors, such as psychosocial barriers to outpatient care (e.g., lack of transporta-
tion to clinic visits). However, such factors cannot explain our observation that nearly all of
these patients were admitted. In addition, NEDS does not track revisits by the same patient, so
some patients may be counted more than once. However, this does not detract from the
importance of our finding that the vast majority of FN patients are admitted. NEDS also pro-
vides limited data on comorbidities that could influence the likelihood of hospitalization.
In conclusion, we have shown that nearly all cancer-associated FN ED visits end in hospital-
ization, that discharge is much more likely in non-metropolitan areas and for patients with
insurance other than public insurance, and that 26% of variation in the hospitalization rate is
due to which hospital the patient visited. We suggest that the available approaches for risk
stratification may be too cumbersome and inaccurate to be useful, with the result being hospi-
talization of nearly all patients, including some who might safely be managed as outpatients.
Simple, objective, valid risk stratification tools are needed.
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